Biosergen

49,00 SEK

+8,88 %

Mindre end 1K følgere

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+8,88 %

+4,02 %

+4,02 %

-22,96 %

-7,56 %

-32,14 %

-33,71 %

-

-86,75 %

Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.

Markedsværdi

115,05 mio. SEK

Aktieomsætning

91,63 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

10.2

2026

Årsrapport '25

6.5

2026

Delårsrapport Q1'26

19.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse20.11.2025, 07.30

Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen

Pressemeddelelse19.11.2025, 13.54

BioStock: Biosergen comments on continued progress in the third quarter

Selskabsmeddelelse19.11.2025, 07.30

Biosergen AB: Biosergen publishes interim report for the third quarter 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse28.10.2025, 07.30

Biosergen AB: Biosergen's Nomination Committee appointed

Pressemeddelelse22.9.2025, 11.43

BioStock: ECDC sounds alarm on C. auris – Biosergen eyes role in containment

Pressemeddelelse17.9.2025, 10.04

Carlsquare: Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe

Pressemeddelelse2.9.2025, 13.40

Carlsquare: Research update Biosergen: Ongoing development going according to plan

Pressemeddelelse21.8.2025, 07.52

BioStock: Biosergen’s CEO on the preparations for the next clinical phase

Selskabsmeddelelse20.8.2025, 06.30

Biosergen AB: Biosergen publishes its interim report for the second quarter 2025

Pressemeddelelse25.7.2025, 10.16

BioStock: Biosergen strengthens executive team amid clinical momentum

Selskabsmeddelelse24.7.2025, 12.12

Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer

Selskabsmeddelelse11.6.2025, 10.01

Bulletin from the annual general meeting in Biosergen AB (publ)

Pressemeddelelse23.5.2025, 08.00

Carlsquare: Research update Biosergen: Stable quarter with exciting news around the corner

Pressemeddelelse21.5.2025, 13.47

BioStock: Biosergen advances antifungal drug with strong Q1 results

Selskabsmeddelelse21.5.2025, 06.30

Biosergen AB: Biosergen publishes interim report for the first quarter 2025

Pressemeddelelse12.5.2025, 11.45

BioStock: Biosergen taps antifungal expert as board member

Selskabsmeddelelse9.5.2025, 13.14

Biosergen AB: Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives

Selskabsmeddelelse9.5.2025, 13.12

Notice of annual general meeting in Biosergen AB

Pressemeddelelse9.5.2025, 12.23

Biosergen AB: BioStock: Biosergen takes aim at climate-driven fungal infections

Pressemeddelelse2.5.2025, 13.17

Biosergen AB: BioStock: Biosergen's CEO on the latest advancements

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.